Sorivudine (BioDeep_00000707106)
代谢物信息卡片
化学式: C11H13BrN2O6 (347.9957)
中文名称: 索立夫定
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=C(C(=O)NC(=O)N1C2C(C(C(O2)CO)O)O)C=CBr
InChI: InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
描述信息
C471 - Enzyme Inhibitor > C2019 - Dihydropyrimidine Dehydrogenase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
D004791 - Enzyme Inhibitors
Sorivudine (BV-araU) is an orally active synthetic pyrimidine nucleoside antimetabolite agent. Sorivudine derives its antiviral activity from selective conversion by a specific thymidine kinase present in certain DNA viruses to nucleotides, which can in turn interfere with viral DNA synthesis[1].
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:32152
- KEGGdrug: D93116
- KEGGdrug: D01734
- PubChem: 5282192
- DrugBank: DB11998
- ChEMBL: CHEMBL70046
- CAS: 77181-69-2
- medchemexpress: HY-123032
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- R Sienaert, G Andrei, R Snoeck, E De Clercq, C McGuigan, J Balzarini. Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase.
Biochemical and biophysical research communications.
2004 Mar; 315(4):877-83. doi:
10.1016/j.bbrc.2004.01.136. [PMID: 14985094] - H Okuda, K Ogura, A Kato, H Takubo, T Watabe. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
The Journal of pharmacology and experimental therapeutics.
1998 Nov; 287(2):791-9. doi:
NULL. [PMID: 9808711] - T Watabe, H Okuda, K Ogura. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
1997 Nov; 117(10-11):910-21. doi:
10.1248/yakushi1947.117.10-11_910. [PMID: 9414600] - H Okuda, T Nishiyama, K Ogura, S Nagayama, K Ikeda, S Yamaguchi, Y Nakamura, Y Kawaguchi, T Watabe. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Drug metabolism and disposition: the biological fate of chemicals.
1997 May; 25(5):270-3. doi:
NULL. [PMID: 9152608] - J Yan, S K Tyring, M M McCrary, P C Lee, S Haworth, R Raymond, S J Olsen, R B Diasio. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
Clinical pharmacology and therapeutics.
1997 May; 61(5):563-73. doi:
10.1016/s0009-9236(97)90136-3. [PMID: 9164418] - H Okuda, T Nishiyama, K Ogura, S Nagayama, K Ikeda, S Yamaguchi, Y Nakamura, K Kawaguchi, T Watabe, Y Ogura. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Drug metabolism and disposition: the biological fate of chemicals.
1997 Feb; 25(2):270-3. doi:
NULL. [PMID: 9029059] - H Nakayama, T Kinouchi, K Kataoka, S Akimoto, Y Matsuda, Y Ohnishi. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
Pharmacogenetics.
1997 Feb; 7(1):35-43. doi:
10.1097/00008571-199702000-00005. [PMID: 9110360] - S Miyauchi, T Imaoka, T Okada, M Motoyama, T Kawaguchi, H Akiyama, M Odomi. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Japanese journal of pharmacology.
1996 Feb; 70(2):139-48. doi:
10.1254/jjp.70.139. [PMID: 8866751] - R J Whitley. Sorivudine: a promising drug for the treatment of varicella-zoster virus infection.
Neurology.
1995 Dec; 45(12 Suppl 8):S73-5. doi:
10.1212/wnl.45.12_suppl_8.s73. [PMID: 8545030] - D B Whigan, A E Schuster. Manual and automated determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in urine.
Journal of chromatography. B, Biomedical applications.
1995 Feb; 664(2):357-63. doi:
10.1016/0378-4347(94)00487-p. [PMID: 7780588] - N Ashida, S Sakata, F Kano, M Nishitani, Y Watanabe, H Machida. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU.
Antiviral research.
1994 Dec; 25(3-4):179-84. doi:
10.1016/0166-3542(94)90001-9. [PMID: 7710267] - N Ashida, K Ijichi, Y Watanabe, H Machida. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Biochemical pharmacology.
1993 Dec; 46(12):2201-7. doi:
10.1016/0006-2952(93)90610-9. [PMID: 8274153] - E Jagoda, M Ogan, B Stouffer, H M Tsay, N Turabi, S Mantha, F Yost, J I Tu. A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Therapeutic drug monitoring.
1992 Dec; 14(6):499-508. doi:
10.1097/00007691-199212000-00011. [PMID: 1485373] - K Soike, J L Huang, J I Tu, B Stouffer, J G Mitroka, M Swerdel, S Olsen, D P Bonner, A V Tuomari, A K Field. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys.
The Journal of infectious diseases.
1992 Apr; 165(4):732-6. doi:
10.1093/infdis/165.4.732. [PMID: 1313071] - D B Whigan, A I Cohen. High-performance liquid chromatographic determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and its metabolite (E)-5-(2-bromovinyl)uracil in serum.
Journal of chromatography.
1991 Aug; 568(2):385-92. doi:
10.1016/0378-4347(91)80176-d. [PMID: 1783644] - S Suzuki, H Machida, M Saneyoshi. Antiviral activity of various 1-beta-D-arabinofuranosyl-E-5-halogenovinyluracils and E-5-bromovinyl-2'-deoxyuridine against salmon herpes virus, Oncorhynchus masou virus (OMV).
Antiviral research.
1987 Feb; 7(2):79-86. doi:
10.1016/0166-3542(87)90023-4. [PMID: 3034148] - T Sakuma. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Antimicrobial agents and chemotherapy.
1984 Jun; 25(6):742-6. doi:
10.1128/aac.25.6.742. [PMID: 6331298] - J Reefschläger, G Herrmann, D Bärwolff, B Schwarz, D Cech, P Langen. Antiherpes activity of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil and some other 5-substituted uracil arabinosyl nucleosides in two different cell lines.
Antiviral research.
1983 Sep; 3(3):175-87. doi:
10.1016/0166-3542(83)90024-4. [PMID: 6316849]
